Akademik Veri Yönetim Sistemi
Journal of B.U.ON., cilt.26, sa.6, ss.2266-2273, 2021 (SCI-Expanded)
Purpose: Oncotype DX 21 gene recurrence score (RS) is commonly used to determine prognosis and the adjuvant therapy decision for patients with estrogen-receptor (ER)-positive, human epidermal growth factor 2(HER 2)-negative, early-stage breast cancer, especially in western countries. The use of this test is limited in Turkey due to its high cost, and the therapy decision is rather made based on clinicopathologic factors. In this study, we aimed to classify Oncotype DX RS according to the TAILOR x risk category in patients with early-stage breast cancer and to demonstrate its correlation with clinicopathologic characteristics. Methods: Oncotype DX RS was classified according to the TAILOR x risk categorization and retrospectively compared in terms of clinicopathologic characteristics in 196 patients with estrogen-receptor (ER)-positive, HER-2 negative, early-stage breast cancer. Results: Oncotype DX RS was found as ≥ 11 in 81.6% of the patients. Out of the patients with low recurrence scores (< 11), 75% had Luminal A and 25% had Luminal B molecular subtypes. The univariate analysis showed a significant correlation between young age (<50 years), low progesterone receptor (PR) immunoreactivity (≤20%), high Ki-67 (≥14) values, and high RS (≥11) and the multivariate analysis found a correlation between high RS (≥11), young age, and low PR immunoreactivity. There was significantly reverse correlation between age and RS. Conclusions: A significant correlation was identified between 11 and above according to the TAILOR x risk categorization and low PR immunoreactivity (≤20%) and young age (<50 years) as classic clinicopathologic factors. Certain clinicopathologic parameters may not be sufficient alone to determine the treatment decision in cases where the Oncotype DX test is not accessible; however, they may have a supportive role.